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Introduction: Non-invasive bladder cancer is effectively treated with intravesical BCG thera-
py. The administration of the BCG vaccine is to destroy the neoplastic lesion or prevent
further recurrences. The activity of the vaccine involves boosting the immune system
through the stimulation of the inﬂammation in the bladder. Adverse reactions after this
immunotherapy are rare.
The aim of the study was to present complications in the form of spinal tuberculosis and
serious neurological symptoms that occurred during intravesical BCG immunotherapy for
carcinoma of the bladder. The manuscript also describes a method for neurosurgical spinal
cord decompression of the thoracic spine.
Material and methods: In the ﬁrst patient, aged 66, after intravesical BCG therapy for bladder
carcinoma, back pain and spastic paralysis of the lower limbs were observed. The MRI and
CT revealed destruction of the intervertebral disc and vertebral endplates Th11–Th12.
Mycobacterium tuberculosis complex bacilli were cultured from the material obtained by
puncture aspiration. In the second patient, aged 35 years, during intravesical BCG immuno-
therapy for carcinoma of the bladder, girdle thoracic spine pain was observed. The MRI and
CT of the spine showed visible lesions characteristic of tuberculosis. Immobilization in a
plaster corset and implementation of antituberculous treatment resulted in quick relief of
the pain and healing of the tuberculosis focus in the spine.
Conclusion: The cases described in the work are the ﬁrst documented reports in the Polish
literature of spinal tuberculosis which occurred as a complication of intravesical administra-
tion of bacilli Calmette–Guérin. The diagnosis was based on the ﬁnding of BCG vaccine bacillus
with molecular methods or PCR. Full antimycobacterial treatment was implemented.
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The BCG vaccine in the form of intravesical instillation is used
to treat bladder cancer. The vaccine contains live attenuated
(malignancy deprived) BCG mycobacteria. BCG as a vaccine
against tuberculosis was developed by A. Calmette and
G. Guérin in 1921 [1]. This strain lost its virulence as a result
of passaging and never returned to its starting level. In Poland,
BCG Moreau mycobacteria are used, derived from a Brazilian
substrain manufactured by the Serum and Vaccine Production
Plant in Lublin. The activity of BCG mycobacteria as a drug
consists in stimulating the immune system of the patient
and also the inﬂammation of the bladder wall. Intravesical
administration of the BCG vaccine is to destroy the cancerous
lesion, prevent further recurrences or delay their occurrence.
The efﬁcacy of BCG immunotherapy for the prevention of
relapse is estimated at 70–90%. The BCG vaccine is used to treat
superﬁcial, epithelial, non-invasive bladder cancer lesions
(Ta, Tis, T1). The discoverer of this method is considered to be
Alvaro Morales who in 1976, together with his colleagues,
announced the ﬁrst results of the intravesical application of
BCG in nine patients with bladder cancer [2]. In Poland, the BCG
vaccine was introduced for the treatment of superﬁcial bladder
cancer by Mazurek et al., and the preliminary results were then
presented in 10 patients [3]. It is believed that the cause of
complications developing in organs at the time of intravesical
immunotherapy is blood-derived spread of BCG bacilli. In the
literature, such complications are described as single cases,
while spinal tuberculosis following intravesical BCG therapy
is extremely rare. The occurrence of undesirable effects is
estimated at 1–10 per million of immunizations made almost
exclusively in patients with impaired immunity. The labora-
tory diagnosis of mycobacterium is very difﬁcult due to the
fact that its genetic structure is not fully known.Fig. 1 – (A) The lateral view of the spine revealed visible destructi
the intervertebral disc. The CT-3D (B), (C) and (D) showed extensi
within the endplates.2. Description of cases
Case 1. Patient K.J., 66 years old, treated for 5 years because of
papillomas of the bladder with intravesical BCG immunother-
apy was admitted to the Orthopedic Department, Subdivision
of Bones and Joints Tuberculosis at Medical Centre of
Postgraduate Education in Otwock, and diagnosed with
tuberculosis of the spine in March 2014. During the examina-
tion, the patient reported back pain encircling the chest and
progressive paralysis of the lower limbs. The neurological
examination revealed weakness of the superﬁcial sensation in
the lower limbs, positive Babinski reﬂex on the right side, 3+
muscle strength on the Lovett scale and features of spasticity
in both legs. X-ray and 3D CT imaging of the spine before the
ﬁrst operation (Fig. 1A–D) showed on the lateral view of the
spine visible kyphus of Th10/Th11 caused by the destruction of
endplates and the intervertebral disc. The CT-3D (Fig. 1C and
D) showed extensive damage to the vertebral body with the
osteosclerotic foci within the endplates.
In the pre-surgery thoracic spine MRI (Fig. 2A–C), destruc-
tion of the intervertebral disc Th10/Th11 with angled bend of
the spine axis was observed. There was low signal in the T1-
dependent image (Fig. 2A) and mixed signal in T2-dependent
images (Fig. 2B). There was also noted an abscess in the spinal
canal (Fig. 2B and C) exerting pressure on the spinal cord.
The chest X-ray showed no changes. The parameters of
inﬂammation were moderately elevated: OB 40 mm, CRP
30 mg/l (N < 6). Fine needle puncture of the focus score in
the spine was performed at the Department of Neurosurgery at
the Medical University of Gdańsk and Mycobacterium tuberculo-
sis was cultured during the ﬁrst stage of bacteriological
diagnosis. During the surgery performed at the Orthopedic
Department, Subdivision of Bones and Joints Tuberculosis at
Medical Centre of Postgraduate Education, the focus score wason of Th10/Th11 caused by the destruction of endplates and
ve damage to the vertebral body with the osteosclerotic foci
Fig. 2 – Destruction of the intervertebral disc Th10/Th11 with angled bend of the spine axis. Low signal in the T1-dependent
image (A) and mixed signal in T2-dependent images (B). An abscess in the spinal canal (B and C) exerting pressure on the
spinal cord.
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anterolateral access through costo-transversectomy (01 April
2014). The chemotherapeutic treatment was continued with
Rifamazid 2  1 capsule, Ethambutol 1  5 capsules, Pyrazi-
namide 3 capsules. The histopathological examination
revealed inﬂamed granulation tissue with Langhans giant
cells. M. tuberculosis complex was cultured with the Bactec
method. Also, the PCR result was positive. In the postoperative
period, the symptoms of back pain and spasticity of the lower
limbs slowly subsided. The patient was put in a plaster corset
and transferred to the Department of Neurological Rehabilita-
tion. After a month stay at the Department of Rehabilitation
no improvement was obtained. In July 2014, the patient
again reported back pain and neurological deterioration that
resulted in almost total paralysis of the lower limbs. In August
2014, there appeared visual disturbances in the form of blurred
vision and color vision disorders. The patient was diagnosed
at the Department of Neurology with toxic neuropathy of the
optic nerves that most likely occurred as a result of the
treatment with Ethambutol. Ethambutol administration was
then discontinued, which stopped the progress of visual
impairment. Imaging diagnostics was performed, namely
X-ray, MRI and CT of the spine.
In MRI (Fig. 3A–D), in the area of Th10/Th11, low signal in
the T1-dependent image was observed (Fig. 3A) and at T2-
dependent image, there was noted mixed signal (Fig. 3B). The
signal became enhanced after administration of gadolinium
(Fig. 3C and D). There was also observed deterioration in the
form of increased peri-vertebrae inﬁltration and high signalcovering the vertebral arches, where it was found that there
occurred higher reduction in vertebral bodies Th10 and Th11
compared with the previous testing and destruction of the
intervertebral disc and epidural inﬁltration within the spinal
canal from the lower part of the vertebral body Th9,
accompanied by signiﬁcant canal stenosis. Due to the
deterioration of the neurological state, the patient was
readmitted to the Department of Orthopedics in Otwock.
Increased neurological disorders were manifested by impaired
feeling in the area from Th12/L1. Additionally, upper and
middle abdominal reﬂexes were weak, and lower were not
observed at all. There was noted paraparesis with increased
spastic muscle tension and bilateral Babinski reﬂex. On 29
September 2014, there was performed revision of the Th11/
Th12 focus score and core decompression at this level. With
the patient laying on the left side, the cut in an old scar was
used to reach the spine at the level of Th9/Th12. Just beneath
the skin, abscess was discovered with curdy masses penetrat-
ing to the spine. The spinal cord was surrounded by curdy
masses and inﬂammatory granulation tissue. The bacterio-
logical examination found tubercle bacilli and the histological
examination revealed tubercular granulation tissue. Addition-
al molecular tests allowed to establish an infection with the
BCG vaccine. This test is regarded as determining the cause of
the infection. To deepen the imaging diagnostics concerning
the extent of the damage of the vertebral bodies related to the
tuberculosis process, CT was performed (Fig. 4).
The 3D CT examination gave the following results: on
selected layers A and B visible damage to the intervertebral
Fig. 3 – In the area of Th10/Th11, low signal in the T1-dependent image (A) and mixed signal at the T2-dependent image (B).
The signal became enhanced after administration of gadolinium (C and D). Deterioration in the form of increased peri-
vertebrae infiltration and high signal covering the vertebral arches, where there occurred higher reduction in vertebral bodies
Th10 and Th11 compared with the previous testing and destruction of the intervertebral disc and epidural infiltration within
the spinal canal from the lower part of Th9, accompanied by significant canal stenosis.
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One rib missing on the right side after surgical removal of the
focus score.
Case 2. Patient C.R., aged 35, treated with intracavitary
attenuated Bacillus Calmette–Guérin therapy due to non-
invasive malignancy at the Department of Urology in Zabrze.
During the 18 months of treatment, no relapse of the cancerFig. 4 – The 3D CT examination: on selected layers A and B
visible damage to the intervertebral disc with the
fragmentation of the vertebral bodies Th10/Th11. One rib
missing on the right side after surgical removal of the focus
score.symptoms was observed. After another intravesical adminis-
tration of bacilli Calmette–Guérin (March 2014), the patient
reported girdle chest pain. No changes in the lungs were found
and the CT scan of the spine and MRI showed focci of
destruction at Th5 6 with an intracanal abscess. A detailed
description is contained in Figs. 5 and 6.
In the lateral projection at the Th5–Th6 level, there was a
small focus score with the destruction of endplates and the
destruction of the rear part of the Th5 vertebral body. The
image of destruction is more visible on the selected layer of the
volume transformation of the thoracic spine Fig. 5C. The cross-
section Fig. 5B shows an area of more severe osteolytic lesions
affecting the Th5 vertebral body. The thoracic spine MR results
are shown in Fig. 6A–C.
The T1-dependent sequence showed marrow edema in the
Th5/T6 vertebral bodies with foci of destruction of endplates,
without any reduction of the height of the vertebral bodies
(Fig. 6A). The signal in the T1-dependent images was enhanced
after contrast administration (Fig. 6B). There was observed
mixed signal in the T2-dependent images. Visible moderate
cord compression at Th5/Th6 was noted as well (Fig. 6C).
The patient was diagnosed with Th5/T6 spondylitis, most
likely due to tuberculosis and was sent to the Subdivision of
Bones and Joints Tuberculosis at Orthopedic Department. The
neurological examination revealed only the positive Babinski
reﬂex, which resolved after the antimycobacterial treatment
was implemented (Rifamazid, Ethambutol, Pyrazinamide) and
relieving the spine in bed. No diagnostic puncture biopsy was
performed. It was concluded that the probability of the spine
infection can also be determined based on a number of indirect
symptoms such as: (1) establishing a causal link of the
infection during the treatment with BCG, (2) positive MTX
test, (3) low parameters of inﬂammation characteristic of the
Fig. 5 – In the lateral projection at the Th5–Th6 level, a small focus score with the destruction of endplates and of the rear part
of the Th5 vertebral body. The image of destruction is more visible on the selected layer of the volume transformation of the
thoracic spine (C). The cross-section (B) shows a more severe osteolytic lesions affecting the Th5 vertebral body.
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bodies osteoporosis visible on the CT scan, and (5) effective TB
treatment.
Relieving the spine in bed was continued for 3 weeks. The
parameters of inﬂammation in the blood considerably
decreased. Then the patient wore a plaster corset while
walking with support for the mandible and occiput. After that,
the patient was discharged home and his state was controlled
in the outpatient clinic (October). Another spinal X-ray showed
healing of the inﬂammation by blocking and kyphotic
reconstruction.
3. Discussion
Extra-bladder complications after intravesical BCG immuno-
therapy for carcinoma of the bladder are rare. Accurate
diagnosis and determination of the type of bacillus is difﬁcult.
In one of the ﬁrst reports in the literature, the infection was
diagnosed in lumbar vertebrae in a 79-year-old man, who
received with intravesical BCG immunotherapy 2.5 years
earlier. The diagnostics was based on culturing the bacillus
from the focus in the spine, while determination of the strain
of Mycobacterium bovis was based on Bactec culture, chro-
matographic tests and the test for PZA resistance [4] since
Tuberculosis bovis is resistant to PZA. Currently, the diagnostics
methods are more accurate and require the use of isotopic,genetic and chromatographic tests [5,6]. Genetic testing should
be considered as complementary and should not substitute
the non-genetic methods. Also the PCR technique has its
limitations, because it detects both viable and nonviable
bacilli. A relatively new test is the so-called MTDT commercial
test (M. tuberculosis Direct Test, Gen-probe, USA). It allows for
the detection of even one bacillus cell in the examined
material. Another molecular test (sensitive) is GTMD (Geno-
type Mycobacteria Direct) [7,8]. This test does not require any
prior culturing of bacillus.
The observed side effects are rare [3,9,10]. They can be
divided into: (1) infectious (infection) and (2) non-infectious
(inﬂammation). Noninfectious complications occur more
frequently. In the literature, they are characterized by
pollakiuria (in 80% of patients), hematuria (40%), and sub-
febrile temperature (40%). These reactions are mild and
disappear after 48 h. Intravesical BCG therapy may also lead
to BCG spreading around the organism. Microdamages of the
bladder are the gates through which BCG mycobacteria can
spread across the surrounding tissue via the circulatory
system. The risk factors are considered to include the
degree of bladder tumor malignancy, cigarette smoking and
advanced age. The risk factors of mycobacteria spreading are
as follows: epithelial damage during catheterization, deep
tumor resection, urethra injury during intravesical bacillus
Calmette–Guérin instillation, bladder outlet obstruction, pelvic
X-irradiation and other forms of severe inﬂammation of the
Fig. 6 – The T1-dependent sequence showed marrow edema in the Th5/T6 vertebral bodies with foci of destruction of
endplates, without any reduction of the height of the vertebral bodies (A). The signal in the T1-dependent images enhanced
after contrast administration (B). Mixed signal in the T2-dependent images. Visible moderate cord compression at Th5/Th6
(C).
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urethral resection of the prostate or bladder biopsy performed
two weeks before BCG administration also predispose patients
to complications. The occurrence of serious complications
after BCG immunotherapy is found in 0.4% of patients [12].
Lamm, in the report published in 2000, stated that the
complications were very rare [13] and appeared in 5% of
2602 patients treated with intravesical bacillus Calmette–
Guérin instillation. The patients manifested fever (1.9%),
miliary TB (0.9%), inﬂammation of the lungs and liver (0.7%),
arthralgia (0.5%), rash (0.3%), renal abscess (0, 1%), sepsis
(0.4%), and anemia (0.1%) [12,25]. The complications described
in literatures related primarily to miliary tuberculosis [9,10,
12,14–17].
Our cases are exceptional. The available literature describes
only six cases of spinal tuberculosis which occurred following
the intravesical administration of bacilli Calmette–Guérin
[4,11,18–21]. In the ﬁrst case presented by the authors, the
clinical diagnosis did not raise any doubts. The microscopic
examination of the material obtained from the focus scorein the spine by ﬁne needle puncture showed the presence of
M. tuberculosis complex. Also the PCR test of the surgical
material was positive, since even from one bacterium it is
possible to obtain a whole series of identical copies of the
genetic material of a mycobacterium [9]. However, the most
important examination determining the etiology was the
molecular method used to detect a BCG vaccine mycobacteri-
um. The case report by Rogoziński et al. concerning granulo-
matous lung inﬂammation following bladder cancer
treatment with BCG vaccine informed of the presence of
granulation with ‘‘caseating tubercules’’, curdy tissue necrosis
resembling Langhans' cells in the situation when genetic
testing of the case for tuberculosis brought negative results
[22]. Despite this, the patient was treated with antimycobac-
terial drugs in accordance with the recommendation [23]. In
our second case (spondylitis after intravesical BCG therapy),
we failed to identify the presence of a mycobacterium. It was
decided not to perform the diagnostic ﬁne needle puncture,
since the probability of tuberculous infection of the spine,
very rapid therapeutic effect after administration of full TB
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vesical BCG administration and the occurrence of spondylitis
conﬁrmed the validity of this diagnosis.
Polish literature describes two cases of complications
following the BCG vaccine treatment of bladder cancer
[22,24]. In one case, granulation tissue was found in the
patient's epididymis [24]. In the second case, suspicion of the
BCG infection led to extending the diagnostics with genetic
and bacteriological testing, and during the examination of
the histopathological material taken by videothoracoscopy,
the presence of granulation tissue and curdy masses was
revealed [22]. Histopathological examination can only deter-
mine tuberculosis, but the type of bacillus is still unknown.
The patient was diagnosed with granulomatous inﬂammation
of the lungs. Nevertheless, it was decided that the best
course will be the full antimycobacterial treatment for 9
months as in the case of bone tuberculosis. Zwolska et al.
described ﬁve cases concerning children, in whom prophylac-
tic vaccination with BCG caused a number of adverse reactions
[6,9]. In the material collected for bacteriological examinations
from suspicious areas and organs in children, the National
Mycobacterium Reference Laboratory found Mycobacterium
bovis [6,9].
Japanese and other authors reported that miliary tubercu-
losis is the most common organ complication (0.9%) induced
by intravesical BCG immunotherapy for carcinoma of the
bladder [9,10,12,14–17,25]. Cough, X-ray and CT examination of
the lungs, transbronchial biopsy of the lung tissue and
detection of M. tuberculosis determine the deﬁnitive diagnosis
and tuberculostatic treatment leads to recovery. However, in
some cases, allergic reactions associated with miliary tuber-
culosis require additional administration of steroids [16]. The
treatment of adverse organ complications after intravesical
administration of bacilli Calmette–Guérin was developed by
the International Bladder Cancer Group [23]. These authors
recommend discontinuation of the intravesical bacillus
Calmette–Guérin instillation and the use of antimycobacterial
drugs, and in the case of particularly severe allergic reactions,
also the additional application of steroids [16]. In our cases,
there was no need for such therapy, because in the ﬁrst case,
the neurological symptoms manifested through paraparesis
were associated with mechanical compression of the spinal
cord and required operative decompression. Complications
during intravesical BCG administration such as miliary
pulmonary tuberculosis and hepatitis are rare, and tubercu-
lous spondylitis – as in our case – is even rarer. The key role is
played by early diagnosis and proper treatment, and careful
qualiﬁcation of patients for BCG therapy and assessment of
risk factors on the basis of the guidelines will make it possible
to avoid serious complications.
Zwolska determined that bacilli of Mycobacterium bovis are
morphologically, physiologically, biochemically and geneti-
cally similar to other species of mycobacterium belonging to
M. tuberculosis complex [6,9]. Such tests were not performed
in our cases. Zwolska also stated that each instance of
complications after the use of BCG mycobacteria should be
reported to the National Mycobacterium Reference Laboratory,
where it is possible to determine the infection with Mycobacte-
rium bovis BCG. That was the case concerning the ﬁrst patient
described by the authors.The authors presented a detailed description of the clinical
diagnostics and the relationship of the infection with
intravesical BCG immunotherapy for the carcinoma of the
bladder and the orthopedic therapeutic intervention. In the
ﬁrst case described by the authors, the patient was treated
surgically for neurological deﬁcits caused by pressure on the
spinal cord. The probability of spinal tuberculosis caused by
the BCG vaccine was described in detail in the text.
4. Conclusion
Intravesical BCG vaccine therapy is a proven treatment for
carcinoma in situ of the bladder. Complications during the
treatment with the BCG vaccine are rare and may affect both
the bladder and other organs such as lungs, liver and also
prostate adjacent to the bladder, epididymis and testicles. On
the other hand, spinal tuberculosis is extremely rare. The
most certain and reliable diagnosis of spinal tuberculosis
is ﬁnding the bacillus in the focus score using ﬁne needle
puncture or in the material obtained during surgery and
having determined whether it is Mycobacterium bovis by the
National Mycobacterium Reference Laboratory. Preventing
the side effects consists predominantly in disseminating the
education/knowledge of such complications, and – during
the therapy – applying the proper technique of BCG vaccine
administration into the bladder. Full antimycobacterial
treatment is mandatory and if there occurs compression
of the spinal cord, it is necessary to perform anterolateral
spinal decompression surgery.
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